{
  "abstract": "Introduction SEQUENCE Part 2 is an open-label extension (OLE) study evaluating long-term efficacy and safety of interleukin-23 p19 inhibitor risankizumab (RZB) in patients (pts) with moderate to severe Crohn’s disease (CD) and prior anti-TNF failure. Here, we evaluated the durability of clinical remission, quality of life (QoL), and inflammatory biomarker outcomes in RZB-treated pts through week (wk) 100 of SEQUENCE.Methods In SEQUENCE, pts randomised to the RZB arm during Part 1 who completed wk48 visit continued to receive open-label 360mg subcutaneous RZB every 8 wks starting at wk52 (Part 2 baseline). 1 We assessed the proportion of pts achieving clinical remission (per CD activity index [CDAI] and stool frequency/abdominal pain score [SF/APS]) and Inflammatory Bowel Disease Questionnaire (IBDQ) remission at wks 8, 24, 52, 76, and 100. Pts with elevated high-sensitivity C-reactive protein (hs-CRP; >5 mg/L) or faecal calprotectin (FCP; >250 µg/g) at baseline were assessed for normalisation at wks 8, 24, 52, 76, and 100. Data were assessed using As Observed (AO) and per Non Responder Imputation (NRI). Safety was not assessed in this post hoc analysis, although previously ­reported.2Results 224 pts entered SEQUENCE Part 2, the proportion of pts who achieved clinical remission (per AO data) increased from wk8 to wk52, and remained stable up to wk100 (CDAI: 48.0% [n/N=96/200] at wk8, 75.3% [168/223] at wk52, and 84.4% [141/167] at wk100; SF/APS: 44.0% [88/200] at wk8, 71.2% [158/222] at wk52, and 74.7% [124/166] at wk100). Similar trends were observed (per AO data) for IBDQ remission (41.5% [88/212] at wk8, 62.1% [139/224] at wk52, and 65.3% [126/193] at wk100), normalisation of hs-CRP (38.8% [54/139] at wk8, 53.1% [76/143] at wk52, and 62.0% [80/129] at wk100), and normalisation of FCP (34.6% [46/133] at wk8, 56.9% [87/153] at wk52, and 60.0% [75/125] at wk100). Most pts who achieved clinical remission at wk8 or at wk52 remained in remission at wk100 (AO data; respectively, CDAI: 96.1% [73/76] and 91.1% [123/135]; SF/APS: 90.1% [64/71] and 86.8% [112/129]). A durable effect was also observed from wk8 to wk100 and from wk52 to wk100 in the majority of RZB-treated pts across all other endpoints (AO data; respectively, IBDQ remission: 91.5% [65/71] and 85.7% [102/119]); normalisation of hs-CRP: 80.0% [40/50] and 81.2% [56/69]; normalisation of FCP: 81.1% [30/37] and 85.1% [57/67]). Similar results to AO data were observed per NRI data.Conclusions Pts receiving RZB demonstrated durable clinical remission, IBDQ remission, and inflammatory biomarker reductions through wk100. Most pts who achieved efficacy endpoints early maintained effectiveness during treatment.References Peyrin-Biroulet L, et al. N Engl J Med. 2024;391:213–23.Peyrin-Biroulet, L et al. Journal of Crohn’s and Colitis, 2025; jjaf213.",
  "authors": [
    {
      "affiliations": [
        "Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany"
      ],
      "name": "Raja Atreya"
    },
    {
      "affiliations": [
        "Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK"
      ],
      "name": "James O Lindsay"
    },
    {
      "affiliations": [
        "University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium"
      ],
      "name": "Marc Ferrante"
    },
    {
      "affiliations": [
        "Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medical Department, Division of Gastroenterology, Infectiology, Rheumatology, Berlin, Germany",
        "Campus Benjamin Franklin, Department of Gastroenterology, Rheumatology, and Infectious Disease, Berlin, Germany"
      ],
      "name": "Britta Siegmund"
    },
    {
      "affiliations": [
        "Sir Run Run Shaw Hospital, College of Medicine Zhejiang University, Department of Gastroenterology, Hangzhou, China"
      ],
      "name": "Qian Cao"
    },
    {
      "affiliations": [
        "AbbVie Inc., North Chicago, USA"
      ],
      "name": "Stijn van Haaren"
    },
    {
      "affiliations": [
        "AbbVie Inc., North Chicago, USA"
      ],
      "name": "Jameson Crowley"
    },
    {
      "affiliations": [
        "AbbVie Inc., North Chicago, USA"
      ],
      "name": "Toni Anschutz"
    },
    {
      "affiliations": [
        "AbbVie Inc., North Chicago, USA"
      ],
      "name": "Andrew Garrison"
    },
    {
      "affiliations": [
        "AbbVie Ltd., Maidenhead, UK"
      ],
      "name": "Christina Coll"
    },
    {
      "affiliations": [
        "Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, USA"
      ],
      "name": "Marla Dubinsky"
    }
  ],
  "title": "P180 Durable efficacy of risankizumab through week 100 in patients with moderately to severely active crohn’s disease: SEQUENCE post hoc analysis",
  "uid": "c686804b-f537-5321-9e51-0b415ca04053"
}